Straumann Holding AG

OTCPK:SAUH.F Stock Report

Market Cap: US$19.9b

Straumann Holding Valuation

Is SAUH.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SAUH.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SAUH.F ($123.42) is trading above our estimate of fair value ($119.76)

Significantly Below Fair Value: SAUH.F is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SAUH.F?

Key metric: As SAUH.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SAUH.F. This is calculated by dividing SAUH.F's market cap by their current earnings.
What is SAUH.F's PE Ratio?
PE Ratio61.8x
EarningsCHF 287.88m
Market CapCHF 17.78b

Price to Earnings Ratio vs Peers

How does SAUH.F's PE Ratio compare to its peers?

The above table shows the PE ratio for SAUH.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average60x
STE STERIS
35.8x11.5%US$21.2b
ZBH Zimmer Biomet Holdings
20.2x8.1%US$21.9b
BAX Baxter International
140.1x39.8%US$17.0b
PODD Insulet
43.8x1.8%US$18.4b
SAUH.F Straumann Holding
61.8x20.9%US$17.8b

Price-To-Earnings vs Peers: SAUH.F is expensive based on its Price-To-Earnings Ratio (61.8x) compared to the peer average (60x).

Price to Earnings Ratio vs Industry

How does SAUH.F's PE Ratio compare vs other companies in the US Medical Equipment Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
MHUA Meihua International Medical Technologies
2xn/aUS$18.77m
PAVM PAVmed
0.7x-77.8%US$10.99m
RTSL Rapid Therapeutic Science Laboratories
0.3xn/aUS$18.99k
UTRS Minerva Surgical
n/an/aUS$8.00
SAUH.F 61.8xIndustry Avg. 37.2xNo. of Companies10PE020406080100+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SAUH.F is expensive based on its Price-To-Earnings Ratio (61.8x) compared to the US Medical Equipment industry average (37.2x).

Price to Earnings Ratio vs Fair Ratio

What is SAUH.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SAUH.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio61.8x
Fair PE Ratio47.5x

Price-To-Earnings vs Fair Ratio: SAUH.F is expensive based on its Price-To-Earnings Ratio (61.8x) compared to the estimated Fair Price-To-Earnings Ratio (47.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SAUH.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$123.42
US$147.89
+19.8%
17.3%US$197.39US$101.51n/a17
Nov ’25US$126.86
US$154.98
+22.2%
16.3%US$202.67US$104.23n/a17
Oct ’25US$162.30
US$161.95
-0.2%
16.4%US$206.78US$106.35n/a18
Sep ’25US$140.59
US$155.56
+10.6%
16.9%US$201.90US$103.83n/a18
Aug ’25US$133.78
US$152.06
+13.7%
18.1%US$198.10US$101.88n/a18
Jul ’25US$128.23
US$149.60
+16.7%
18.4%US$194.81US$100.19n/a18
Jun ’25US$125.83
US$149.97
+19.2%
18.2%US$193.06US$99.29n/a18
May ’25US$130.34
US$150.87
+15.8%
18.4%US$190.40US$97.92n/a18
Apr ’25US$153.90
US$157.40
+2.3%
18.4%US$193.55US$99.54n/a19
Mar ’25US$160.74
US$151.79
-5.6%
17.7%US$189.99US$101.78n/a18
Feb ’25US$158.37
US$147.26
-7.0%
16.1%US$175.72US$103.36n/a18
Jan ’25US$159.37
US$144.60
-9.3%
15.2%US$172.94US$103.77n/a17
Dec ’24US$134.49
US$142.15
+5.7%
14.8%US$171.31US$102.79n/a17
Nov ’24US$113.50
US$145.39
+28.1%
16.8%US$183.96US$99.14US$126.8617
Oct ’24US$127.10
US$148.44
+16.8%
18.0%US$183.11US$98.68US$162.3016
Sep ’24US$154.48
US$155.87
+0.9%
17.7%US$190.24US$102.53US$140.5917
Aug ’24US$161.17
US$150.15
-6.8%
20.4%US$184.24US$91.56US$133.7817
Jul ’24US$156.82
US$148.67
-5.2%
21.1%US$183.39US$91.14US$128.2317
Jun ’24US$150.60
US$146.56
-2.7%
22.3%US$183.37US$91.13US$125.8316
May ’24US$143.75
US$138.02
-4.0%
21.4%US$176.86US$90.64US$130.3415
Apr ’24US$147.60
US$135.42
-8.3%
21.8%US$173.98US$89.17US$153.9015
Mar ’24US$130.95
US$128.67
-1.7%
21.2%US$168.81US$85.47US$160.7414
Feb ’24US$129.17
US$126.00
-2.5%
20.4%US$162.63US$86.73US$158.3714
Jan ’24US$116.25
US$128.06
+10.2%
18.7%US$161.43US$94.70US$159.3713
Dec ’23US$113.25
US$128.56
+13.5%
17.9%US$161.12US$94.78US$134.4912
Nov ’23US$93.70
US$129.11
+37.8%
23.9%US$204.72US$89.88US$113.5013

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Lantheus Holdings

US$6.3b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$90.52

7D

18.8%

1Y

27.5%

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

ELV

US$402.55

7D

0.5%

1Y

-15.7%

electroCore

US$72.3m

A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.

ECOR

US$11.21

7D

16.2%

1Y

99.5%